ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

If a Mount Rushmore of Epidemiology were to exist, Joseph F. Fraumeni Jr. would be etched into the face of the mountain, former NCI Director Ned Sharpless once told Stephen J. Chanock.

Cancer progress is not reaching everyone. Native Nations must be part of the solution.

In 1971, the National Cancer Act set the United States on a path to confront one of its most formidable public health challenges. More than five decades later, the progress is undeniable. The latest 2026 report from the American Cancer Society shows continued declines in overall cancer mortality and improvements in survival for many major cancer types. Recent advances in early detection, prevention, and treatment are saving lives.

July 17, 2026

Vol.52 No.28

By Rodney Haring

Clinical Trials & Tribulations

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives

I performed my first colonoscopy as a board-certified gastroenterologist more than 20 years ago, at a time when the procedure was firmly established as the “gold standard” for colorectal cancer screening.

July 02, 2026

Vol.52 No.26

By Paul J. Limburg

Clinical Trials & Tribulations

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.”

The world of cancer research has lost one of its brightest and gentlest stars, Joseph F. Fraumeni, Jr., MD, the founding director of NCI’s Division of Cancer Epidemiology and Genetics within the Intramural Research Program of the National Institutes of Health.

June 26, 2026

Vol.52 No.25

By Stephen J. Chanock

In Brief

American Cancer Society names four members to Board of Directors

The American Cancer Society has appointed four members to its Board of Directors. Together, they will help guide how the American Cancer Society sets priorities, stewards resources, and measures progress, ensuring the organization remains focused on delivering meaningful impact for cancer patients and their families.

May 08, 2026

Vol.52 No.18

ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

YOU MAY BE INTERESTED IN

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

Cancer progress is not reaching everyone. Native Nations must be part of the solution.

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.”

American Cancer Society names four members to Board of Directors

Renew today!

Subscriber content

Never miss an issue!

Login

ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

YOU MAY BE INTERESTED IN

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”Chanock and Brawley reflect on their illustrious mentor

Cancer progress is not reaching everyone. Native Nations must be part of the solution.

Is it time to re-assess the practice and practicality of screening colonoscopy?Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives

More than 50 million Americans remain unscreened for colon cancerNew guidelines offer another option

Joe Fraumeni, founder of molecular epidemiology, dies at 93“It’s hard to imagine a world without the presence of this gentle scientific giant.”

American Cancer Society names four members to Board of Directors

Never miss an issue!

Login

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.”